Voya Investment Management LLC Lowers Position in Haemonetics Corporation $HAE

Voya Investment Management LLC trimmed its holdings in shares of Haemonetics Corporation (NYSE:HAE) by 17.7% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 48,211 shares of the medical instruments supplier’s stock after selling 10,393 shares during the period. Voya Investment Management LLC’s holdings in Haemonetics were worth $2,350,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Quarry LP boosted its position in shares of Haemonetics by 63.4% during the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 192 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares in the last quarter. GAMMA Investing LLC lifted its position in Haemonetics by 59.4% during the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock valued at $33,000 after purchasing an additional 165 shares during the last quarter. UMB Bank n.a. lifted its position in Haemonetics by 91.7% during the second quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier’s stock valued at $50,000 after purchasing an additional 320 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC purchased a new position in Haemonetics in the 2nd quarter worth approximately $64,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Up 0.3%

HAE opened at $80.27 on Friday. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $87.32. The company has a current ratio of 1.64, a quick ratio of 1.03 and a debt-to-equity ratio of 1.08. The business’s 50-day moving average price is $71.47 and its 200-day moving average price is $65.17. The company has a market cap of $3.76 billion, a P/E ratio of 23.47, a P/E/G ratio of 1.51 and a beta of 0.30.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.15. The company had revenue of $327.32 million during the quarter, compared to analysts’ expectations of $311.61 million. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.Haemonetics’s quarterly revenue was down 5.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.12 EPS. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, equities analysts expect that Haemonetics Corporation will post 4.55 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on HAE. Weiss Ratings restated a “hold (c)” rating on shares of Haemonetics in a research report on Monday, December 22nd. Wall Street Zen downgraded Haemonetics from a “buy” rating to a “hold” rating in a research report on Sunday, December 14th. Robert W. Baird upped their price objective on Haemonetics from $87.00 to $99.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. BTIG Research reissued a “buy” rating and set a $88.00 price objective on shares of Haemonetics in a report on Friday, November 21st. Finally, CJS Securities upgraded Haemonetics to a “strong-buy” rating in a research report on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $84.10.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.